On July 30, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, reported its long-standing collaboration with the University of British Columbia (UBC) and its affiliated Vancouver Prostate Centre (VPC), one of Canada’s leading cancer research institutions (Press release, Rakovina Therapeutics, JUL 30, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-highlights-long-standing-collaboration-with-the-university-of-british-columbia-and-the-vancouver-prostate-centre [SID1234654687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rakovina’s collaboration with the Vancouver Prostate Centre and UBC ensures that compound testing and validation are conducted within one of the world’s most respected cancer facilities. This agreement with UBC enables close collaboration with leading cancer scientists using UBC’s state-of-the-art lab infrastructure, both accelerating and de-risking the translation of scientific discovery.

Furthermore, members of Rakovina’s management team and scientific advisory board hold dual roles within UBC and the Vancouver Prostate Centre, strengthening the connection.

Rakovina’s President and Chief Scientific Officer, Dr. Mads Daugaard, serves as an Associate Professor at UBC and as Senior Research Scientist and Head of Molecular Pathology at the Vancouver Prostate Centre. His dual roles in academia and industry bridge fundamental cancer biology with Rakovina’s proprietary DDR drug discovery programs.

The Company’s AI and medicinal chemistry advisor, Dr. Artem Cherkasov, is a Senior Research Scientist and Head of Precision Cancer Drug Design at the Vancouver Prostate Centre, Professor in the Department of Urologic Sciences at UBC, and Canada Research Chair in Precision Cancer Drug Design. A pioneer in AI-enabled drug discovery, Dr. Cherkasov is the developer of the Deep Docking platform, which drives part of Rakovina’s drug discovery engine and has accelerated the identification of novel DDR inhibitors.

"Our model has been built on strategic alignment with UBC’s research excellence," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "Collaborating with the Vancouver Prostate Centre gives us unique access to the infrastructure, expertise, and collaborative environment needed to rapidly advance next-generation cancer therapies."

Rakovina Therapeutics continues to leverage its deep academic partnerships as it advances multiple oncology programs toward preclinical milestones.